|June 26, 2013|
|20:30 EDT||SCMP||Sucampo receives $10M milestone payment from Takeda|
Sucampo Pharmaceuticals announced that it has received a $10M milestone payment from Takeda, pursuant to the existing collaboration and license agreement between SPI and Takeda. The milestone payment was triggered by the commercial launch of AMITIZA in the United States for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain. This is the third indication for AMITIZA.
News For SCMP From The Last 14 Days
Check below for free stories on SCMP the last two weeks.
|August 1, 2014|
|10:00 EDT||SCMP||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at Citigroup... Casella Waste (CWST) initiated with a Hold at Stifel... CymaBay Therapeutics (CBAY) initiated with an Outperform at Cowen... Finish Line (FINL) initiated with a Buy at Jefferies... Flamel Technologies (FLML) initiated with an Outperform at Leerink... PTC Therapeutics (PTCT) initiated with an Outperform at Oppenheimer... Paramount Gold & Silver (PZG) initiated with a Buy at Noble Financial... Progressive Waste (BIN) initiated with a Hold at Stifel... Prosensa (RNA) initiated with an Outperform at Oppenheimer... Sangamo (SGMO) initiated with an Overweight at JPMorgan... Sarepta (SRPT) initiated with an Outperform at Oppenheimer... Sucampo (SCMP) initiated with a Buy at Roth Capital.
|08:39 EDT||SCMP||Sucampo initiated with a Buy at Roth Capital|
|July 25, 2014|
|16:45 EDT||SCMP||S&R Foundation reports 6.3% stake in Sucampo |
Subscribe for More Information
|July 23, 2014|
|06:51 EDT||SCMP||Sucampo announces publication of NICE recommendatoin for Amitiza|
Sucampo announced that the United Kingdom's National Institute of Health and Care Excellence has published the technology appraisal guidance recommending the use of AMITIZA in the treatment of chronic idiopathic constipation and associated symptoms in adults who have failed laxatives. The NICE guidance recommends AMITIZA as an option for treating CIC for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered.
|July 22, 2014|
|15:12 EDT||SCMP||Sucampo says FDA approves addition of Nitto Medic as Rescula production site|
Sucampo Pharmaceuticals disclosed in a regulatory filing that on July 15 the company received an approval letter from the FDA to its prior approval supplement in response to FDA’s review of the revised Drug Master File of R-Tech Ueno. The approval provides for the addition of Nitto Medic of Toyama, Japan as a new production site for Rescula 0.15%. "The company has adequate supply of RESCULA to be able to supply the U.S. market into the first quarter of 2015," Sucampo added.